<p>怀俄明州在最近向证券交易委员会的披露中表示，在第四季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股增加了 293.0%。该基金在季度内购买了额外的 16,652 股后，持有 22,335 股这家生物制药公司的股票。根据最近向证券交易委员会的备案，怀俄明州在辉瑞的持股价值为 593,000 美元。</p>
<ul>
<li>3 只高收益分红股票，可能在 52 周低点附近反弹</li>
</ul>
<p>其他几家机构投资者也最近增加或减少了在该公司的股份。Tallon Kerry Patrick 在第四季度购买了价值约 509,000 美元的辉瑞新股份。Merit Financial Group LLC 在第四季度将其在辉瑞的持股增加了 60.8%。Merit Financial Group LLC 现在拥有 127,967 股这家生物制药公司的股票，价值 3,395,000 美元，此前在该期间内又购买了 48,397 股。Sax Wealth Advisors LLC 在第四季度将其在辉瑞的持股增加了 17.4%。Sax Wealth Advisors LLC 现在拥有 10,995 股这家生物制药公司的股票，价值 292,000 美元，此前在该期间内又购买了 1,630 股。Lake Street Private Wealth LLC 在第四季度将其在辉瑞的持股增加了 8.3%。Lake Street Private Wealth LLC 现在拥有 10,096 股这家生物制药公司的股票，价值 268,000 美元，此前在该期间内又购买了 776 股。最后，Ameritas Advisory Services LLC 在第四季度将其在辉瑞的持股增加了 3.6%。Ameritas Advisory Services LLC 现在拥有 75,983 股这家生物制药公司的股票，价值 2,016,000 美元，此前在该期间内又购买了 2,633 股。目前 68.36% 的股票由机构投资者和对冲基金持有。</p>
<h2>辉瑞股价上涨 1.0%</h2>
<p>辉瑞（NYSE PFE）周一开盘价为 22.83 美元。该股票的 50 日移动平均价格为 23.65 美元，200 日移动平均价格为 25.32 美元。辉瑞公司的 52 周低点为 20.92 美元，52 周高点为 31.54 美元。该股票的市值为 1,297.7 亿美元，市盈率为 16.19，市盈增长比率为 0.64，贝塔值为 0.58。该公司的速动比率为 0.73，流动比率为 1.00，债务与股本比率为 0.63。</p>
<ul>
<li>2 只医疗保健股票值得关注，因为摩根大通提升了吉利德的评级</li>
</ul>
<p>辉瑞（NYSE:PFE - 获取免费报告）最近在 4 月 29 日（星期二）公布了季度财报。这家生物制药公司报告的每股收益（EPS）为 0.92 美元，超出市场普遍预期的 0.67 美元，超出幅度为 0.25 美元。辉瑞的股本回报率为 19.47%，净利润率为 12.62%。该公司在本季度的收入为 137.2 亿美元，而分析师的预期为 144.3 亿美元。在去年同期，该公司每股收益为 0.82 美元。辉瑞本季度的收入较去年同期下降了 7.8%。分析师预计辉瑞公司在当前财政年度的每股收益将达到 2.95 美元。</p>
<h2>辉瑞宣布分红</h2>
<p>该公司还最近披露了季度分红，将于 6 月 13 日（星期五）支付。5 月 9 日（星期五）的股东将获得每股 0.43 美元的分红。这相当于每年 1.72 美元的分红，收益率为 7.54%。除息日为 5 月 9 日（星期五）。辉瑞的派息比率目前为 124.64%。</p>
<h2>华尔街分析师的看法</h2>
<ul>
<li>Viking Therapeutics：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
<p>几位股票研究分析师最近对该公司发表了看法。汇丰全球研究在 3 月 10 日（星期一）的研究报告中将辉瑞的评级提升至 “强力买入”。Cantor Fitzgerald 在 4 月 22 日（星期二）的研究报告中开始覆盖辉瑞，给予 “中性” 评级和 24.00 美元的目标价。高盛集团在 4 月 8 日（星期二）的研究报告中重申了辉瑞的 “中性” 评级，并将目标价下调至 25.00 美元（之前为 32.00 美元）。Guggenheim 在 3 月 18 日（星期二）的报告中重申了辉瑞的 “买入” 评级。最后，瑞银集团在 4 月 30 日（星期三）的报告中将辉瑞的目标价从 24.00 美元提高至 25.00 美元，并给予该公司 “中性” 评级。一位研究分析师对该股票给予了卖出评级，八位给予持有评级，四位给予买入评级，三位给予强力买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 29.17 美元。</p>
<p><strong>阅读我们关于辉瑞的最新报告</strong></p>
<h2>辉瑞公司简介</h2>
<p>（免费报告）</p>
<p>辉瑞公司在美国、欧洲及国际上发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；针对未满足医疗需求的传染病，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及未来潜在的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过辉瑞</li>
<li>安静期到期的解释</li>
<li>Nextracker 的太阳能激增：它会打破历史最高纪录吗？</li>
<li>内部人士出售的解释：它能否为你的投资选择提供信息？</li>
<li>精明的投资者为喜力股票举杯庆祝</li>
<li>什么是日经 225 指数？</li>
<li>关税减免后，中国投资的四大 ETF</li>
</ul>
<p><strong>想看看其他对冲基金持有的 PFE 吗？</strong> 访问 HoldingsChannel.com，获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 备案和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>这条即时新闻提醒是由叙事科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

辉瑞

<p>怀俄明州在第四季度将其在辉瑞公司（NYSE:PFE）的持股增加了 293%，目前持有 22,335 股，价值 593,000 美元。其他机构投资者也增加了他们的持股。辉瑞的股票开盘价为 22.83 美元，市值为 1297.7 亿美元。公司报告第一季度每股收益为 0.92 美元，超出预期，但收入同比下降了 7.8%。辉瑞宣布每股季度分红为 0.43 美元，收益率为 7.54%。分析师的评级意见不一，普遍评级为 “适度买入”，平均目标价为 29.17 美元</p>

<p>State of Wyoming boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 293.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,335 shares of the biopharmaceutical company's stock after purchasing an additional 16,652 shares during the quarter. State of Wyoming's holdings in Pfizer were worth $593,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>怀俄明州在最近向证券交易委员会的披露中表示，在第四季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股增加了 293.0%。该基金在季度内购买了额外的 16,652 股后，持有 22,335 股这家生物制药公司的股票。根据最近向证券交易委员会的备案，怀俄明州在辉瑞的持股价值为 593,000 美元。</p>
</div><ul>
<li>3 High-Yield Dividend Stocks That Could Rally Near 52-Week Lows</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只高收益分红股票，可能在 52 周低点附近反弹</li>
</ul>
</div><p>Several other institutional investors have also recently added to or reduced their stakes in the business. Tallon Kerry Patrick purchased a new stake in Pfizer during the fourth quarter valued at about $509,000. Merit Financial Group LLC grew its position in Pfizer by 60.8% during the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company's stock valued at $3,395,000 after acquiring an additional 48,397 shares during the period. Sax Wealth Advisors LLC grew its position in Pfizer by 17.4% during the fourth quarter. Sax Wealth Advisors LLC now owns 10,995 shares of the biopharmaceutical company's stock valued at $292,000 after acquiring an additional 1,630 shares during the period. Lake Street Private Wealth LLC grew its position in Pfizer by 8.3% during the fourth quarter. Lake Street Private Wealth LLC now owns 10,096 shares of the biopharmaceutical company's stock valued at $268,000 after acquiring an additional 776 shares during the period. Finally, Ameritas Advisory Services LLC grew its position in Pfizer by 3.6% during the fourth quarter. Ameritas Advisory Services LLC now owns 75,983 shares of the biopharmaceutical company's stock valued at $2,016,000 after acquiring an additional 2,633 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家机构投资者也最近增加或减少了在该公司的股份。Tallon Kerry Patrick 在第四季度购买了价值约 509,000 美元的辉瑞新股份。Merit Financial Group LLC 在第四季度将其在辉瑞的持股增加了 60.8%。Merit Financial Group LLC 现在拥有 127,967 股这家生物制药公司的股票，价值 3,395,000 美元，此前在该期间内又购买了 48,397 股。Sax Wealth Advisors LLC 在第四季度将其在辉瑞的持股增加了 17.4%。Sax Wealth Advisors LLC 现在拥有 10,995 股这家生物制药公司的股票，价值 292,000 美元，此前在该期间内又购买了 1,630 股。Lake Street Private Wealth LLC 在第四季度将其在辉瑞的持股增加了 8.3%。Lake Street Private Wealth LLC 现在拥有 10,096 股这家生物制药公司的股票，价值 268,000 美元，此前在该期间内又购买了 776 股。最后，Ameritas Advisory Services LLC 在第四季度将其在辉瑞的持股增加了 3.6%。Ameritas Advisory Services LLC 现在拥有 75,983 股这家生物制药公司的股票，价值 2,016,000 美元，此前在该期间内又购买了 2,633 股。目前 68.36% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Pfizer Trading Up 1.0%</h2>
<div class="lb-trans"><h2>辉瑞股价上涨 1.0%</h2>
</div><p>Shares of NYSE PFE opened at $22.83 on Monday. The stock's 50 day moving average price is $23.65 and its two-hundred day moving average price is $25.32. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The stock has a market capitalization of $129.77 billion, a P/E ratio of 16.19, a PEG ratio of 0.64 and a beta of 0.58. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.</p>
<div class="lb-trans"><p>辉瑞（NYSE PFE）周一开盘价为 22.83 美元。该股票的 50 日移动平均价格为 23.65 美元，200 日移动平均价格为 25.32 美元。辉瑞公司的 52 周低点为 20.92 美元，52 周高点为 31.54 美元。该股票的市值为 1,297.7 亿美元，市盈率为 16.19，市盈增长比率为 0.64，贝塔值为 0.58。该公司的速动比率为 0.73，流动比率为 1.00，债务与股本比率为 0.63。</p>
</div><ul>
<li>2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只医疗保健股票值得关注，因为摩根大通提升了吉利德的评级</li>
</ul>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the prior year, the firm posted $0.82 earnings per share. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最近在 4 月 29 日（星期二）公布了季度财报。这家生物制药公司报告的每股收益（EPS）为 0.92 美元，超出市场普遍预期的 0.67 美元，超出幅度为 0.25 美元。辉瑞的股本回报率为 19.47%，净利润率为 12.62%。该公司在本季度的收入为 137.2 亿美元，而分析师的预期为 144.3 亿美元。在去年同期，该公司每股收益为 0.82 美元。辉瑞本季度的收入较去年同期下降了 7.8%。分析师预计辉瑞公司在当前财政年度的每股收益将达到 2.95 美元。</p>
</div><h2>Pfizer Announces Dividend</h2>
<div class="lb-trans"><h2>辉瑞宣布分红</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.54%. The ex-dividend date is Friday, May 9th. Pfizer's payout ratio is currently 124.64%.</p>
<div class="lb-trans"><p>该公司还最近披露了季度分红，将于 6 月 13 日（星期五）支付。5 月 9 日（星期五）的股东将获得每股 0.43 美元的分红。这相当于每年 1.72 美元的分红，收益率为 7.54%。除息日为 5 月 9 日（星期五）。辉瑞的派息比率目前为 124.64%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><ul>
<li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
</div><p>Several equities research analysts have recently weighed in on the company. Hsbc Global Res raised Pfizer to a &#34;strong-buy&#34; rating in a research report on Monday, March 10th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a &#34;neutral&#34; rating and a $24.00 target price for the company. The Goldman Sachs Group reaffirmed a &#34;neutral&#34; rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim reissued a &#34;buy&#34; rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the company a &#34;neutral&#34; rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $29.17.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该公司发表了看法。汇丰全球研究在 3 月 10 日（星期一）的研究报告中将辉瑞的评级提升至 “强力买入”。Cantor Fitzgerald 在 4 月 22 日（星期二）的研究报告中开始覆盖辉瑞，给予 “中性” 评级和 24.00 美元的目标价。高盛集团在 4 月 8 日（星期二）的研究报告中重申了辉瑞的 “中性” 评级，并将目标价下调至 25.00 美元（之前为 32.00 美元）。Guggenheim 在 3 月 18 日（星期二）的报告中重申了辉瑞的 “买入” 评级。最后，瑞银集团在 4 月 30 日（星期三）的报告中将辉瑞的目标价从 24.00 美元提高至 25.00 美元，并给予该公司 “中性” 评级。一位研究分析师对该股票给予了卖出评级，八位给予持有评级，四位给予买入评级，三位给予强力买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 29.17 美元。</p>
</div><p><strong>Read Our Latest Report on Pfizer</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于辉瑞的最新报告</strong></p>
</div><h2>Pfizer Company Profile</h2>
<div class="lb-trans"><h2>辉瑞公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>辉瑞公司在美国、欧洲及国际上发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；针对未满足医疗需求的传染病，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及未来潜在的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>Quiet Period Expirations Explained</li>
<li>Nextracker’s Solar Surge: Will It Shatter Its All-Time High?</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>Savvy Investors Are Raising a Glass for Heineken Stock</li>
<li>What is the Nikkei 225 index?</li>
<li>Top 4 ETFs for China Exposure After Tariff Relief</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过辉瑞</li>
<li>安静期到期的解释</li>
<li>Nextracker 的太阳能激增：它会打破历史最高纪录吗？</li>
<li>内部人士出售的解释：它能否为你的投资选择提供信息？</li>
<li>精明的投资者为喜力股票举杯庆祝</li>
<li>什么是日经 225 指数？</li>
<li>关税减免后，中国投资的四大 ETF</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PFE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 PFE 吗？</strong> 访问 HoldingsChannel.com，获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 备案和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这条即时新闻提醒是由叙事科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Pfizer Inc. (NYSE:PFE) Shares Bought by State of Wyoming

- 怀俄明州在第四季度将其在辉瑞公司的持股增加了 293.0%。
- 该州持有辉瑞 22,335 股，市值约为 593,000 美元。
- 68.36% 的辉瑞股票目前由机构投资者和对冲基金持有。

怀俄明州购买了辉瑞公司（NYSE:PFE）的股票